Abstract
is yet unknown. There is a racial variation in susceptibility with a reported in incidence in Asian children of 9-16/100,000 7, 8 in comparison to 2 to 7 children in USA 3 , 2-4 new cases /100,000 children in UK 8, 9 . Mortality was 50/1000 before antibiotic and steroid, which is now 5/1000 10 .
Age and sex: The peak incidence of both MCNS and FSGS in pre-school age children, 80% of nephrotic children are less than 6 years old at presentation, with the median age at diagnosis being 2.5 years for MCNS and 6.0 years for FSGS 11, 12 . The mean age at onset has been reported to be 3.4 years in Asians and 4.2 years in Europeans. In young children, boys are more commonly affected than girls (ratio 3:2) but in teenagers and adults, the sex ratio is approximately equal. 11
Race: There is variation in the overall prevalence of NS in children and in the relative frequency of the different histological categories in different population. In the UK, there is higher prevalence of MCNS in children of families from the Indian subcontinent, than in the indigenous Caucasian population 3, 12 .
Genetic Aspects: Nephrotic syndrome is familial in 2-8% cases and in most cases siblings are involve 13 . Familial cases appear to be inherited in a polygenic fashion. The condition is much common in monozygotic twins than in dizygotic, which suggest that genetic factors play a more important role than environmental factors. It is reported that patients with steroid responsive nephrotic syndrome more frequently have the combined occurrence of HLA-DR3; HLA-DR7 and HLA -B8-DR3 where as patient with steroid resistant nephrotic syndrome more frequently have the combined occurrence of HLA-B8-DR8 and DR7.
Pathogenesis:
The pathogenesis of nephrotic syndrome still not identified. There is a strong evidence of immune dysregulation, mainly involving cell-mediated immunity (CMI). The tendency of nephrotic syndrome to manifest and relapse after viral infections or an atopic episode, the association with HLA antigens and the therapeutic response to steroids and cyclosporine A (CsA) support this view. Prolonged remissions following measles, which downregulates CMI also endorses this hypothesis. T-cell abnormalities has been variably reported in minimal change disease (MCD) 14, 15, 16, 17 . Increased free radical generations and decreased anti oxidantdefenses may play crucial role in the pathogenesis of nephrotic syndrome. 16 Immunological Dysfunction: Immune response has been applied to know the pathogenesis of nephrotic syndrome. Antigen presentation to T-lymphocytes induces immune response, which may be Type 1 [dominated by α-interferon, interleukin (IL) 2] or Type-2 (IL4, IL10 or IL13). Type 1 cytokines predominate in cell-mediated immunity and Type 2 cytokines in some aspects of humoral immunity. Type 2 cytokines are particularly associated with atopy and class switching of B cells for production of IgG4 and IgE. Increased plasma levels of IgE, with normal IgG4 (with decreased IgG1 and IgG2), and association with atopy suggest type 2 cytokine bias in subjects with Minimal Change Disease (MCD). The mechanisms by which the cytokine bias might affect glomerular permeability is still not clear. Recent evidence suggests an activations of innate immunity in response to triggering of toll like receptors (TLRs) by microbial products, may directly affects podocytes. 13 In vitro studies suggest that podocytes express receptors for IL4 and IL13 may disrupt glomerular permeability and resulting in proteinuria. The benefits on treatment with levamisole, which augments type 1 and downregulates type 2 cytokines also support the above hypothesis 18 .
Role of permeability factor: In minimal change and focal segmental glomerulo sclerosis, systemic circulating factor, may increase glomerular permeability.Various vascular permeability factors including vascular endothelial growth factor, heparanase and hemopexin may be involved 19 .
Genetics:
Genetic Mutations are present in 10-30% of sporadic onset steroid-resistant and in higher proportions of patients with familial nephrotic syndrome. Mutations in genes encoding several podocyte proteins have been identified in children with familial nephrotic syndrome ( Table-I ). This mutation involves the NPHS1 gene, encoding the protein nephrin. This transmembrane protein is present in the slit diaphragm in between the podocytes 20, 21 . Mutations in nephrin are responsible for the congenital Finnish nephrotic syndrome 22 . Abnormalities of another gene, the NPHS2 gene encoding podocin, results in recessively inherited FSGS. Recent evidence suggests that the primary defect in idiopathic nephrotic syndrome might be at the level of podocyte (the glomerular visceral epithelial cell). Podocyte injury or structural inherited defects are implicated in the occurrence of glomerular proteinuria. Some viruses like HIV, parvovirus B19 may directly cause injury to the podocyte 20 . The role of immunosuppressive medications with these mutations 23 is limited and ultimately progress to end stage renal disease. Other implicated genes are WT1 (Wilms' tumour suppressor gene), FSGS2 and LMX1B (nail patella syndrome). Mutations in WT1 are associated with Denys-Drash syndrome and Frasier syndrome 23 . 
Steroid Sensitive Nephrotic Syndrome (SSNS):
The disease course is variable; while almost 40% have no relapses or a single relapse, more than 55% show multiple relapses that occur either infrequently or frequently. Usually within 7 to 10 days most of children will respond to steroid 27 .
Evaluation at Onset: Treatment with corticosteroids starts with detailed evaluations. That includes history and physical examination (height, weight and blood pressure), with attention to detect infections and underlying systemic disorders.
Indication for renal biopsy: 28
A biopsy is usually not necessary in patients with frequent relapse or steroid dependence or before starting treatment with levamisole, cyclophosphamide, or MMF (Mycophenolate Mofetil), but should be performed before therapy with calcineurin inhibitors. Biopsy is also necessary in cases including: (a) Age of onset<1 year (b) Gross hematuria, persistent microscopic hematuria or low serum C3, (c) Sustained hypertension (d) Renal failure not attributable to hypovolemia (e) Suspected secondary causes of nephrotic syndrome, (f)if Proteinuria persisting despite 8-weeks of daily corticosteroid therapy and (g) Before treatment with cyclosporine A or tacrolimus. Supportive care: Intensive supportive care is an important aspect of managing children with nephrotic syndrome.
Management of the initial episodes:
Edema: Edema or anasarca is associated with an increased risk of infections. 
Stress dose of steroids:
Patients who have received steroids at high doses for more than 2 week in the past year are at risk of suppression of the hypothalamopituitary-adrenal axis. These children require steroid supplements during surgery, anesthesia or serious infections. Steroids are given at a dose of.2-4 mg/kg/ day (IV Hydrocortisone) followed by oral prednisolone at 0.3 to 0.6 mg/kg/d up to stress period and then tapered rapidly 40 .
Specific Management
The initial (first) episode of nephrotic syndrome should be treated adequately as it is important determinant of long term course.
Drugs or medications:
The standard medication for treatment is prednisolone or prednisone. This drug is applied after meals to reduce gastrointestinal side effects. Different treatment regimens have been used for initial episode of nephrotic syndrome.
The International Study of Kidney Diseases in
Children (ISKDC) regimen: Prednisolone 60 mg/ m 2 /day in 3 divided doses (max 80 mg/day) followed by 40mg/m 2 /day (max 60 mg/day) on alternate day for 4 weeks 42 . But this regimen is associated with a higher relapse rate. So, prolongation of initial steroid therapy (2mg/kg/day maximum 60 mg in single or divided dose for 6 weeks followed by 1.5mg/kg as a single morning dose on alternate day for 6 weeks) for 12 week or longer is associated with significantly reduced risk of subsequent relapses. This regimen is associated with higher frequency of adverse events.
The Cochrane group 43 44 .
Indian Academy of Paediatrics ( IAP):
Based on current evidence, this group also recommends the six weeks regimens (Fig.-3) .
The Arbeitsgemeinschaft für Pädiatrische Nephrologie (APN):
The daily dose of 60 mg/m 2 / day for 4 weeks and the starting dose of 40 mg/m 2 for alternate day therapy were also used empirically by the APN 45, 46 and have not been examined in RCTs so while these doses are recommended, the quality of evidence supporting these data is very low. APN has demonstrated a reduction in RR for relapse in cyclosporine (150 mg/m 2 /day for 8 weeks) and prednisolone compared with prednisolone alone for 6 months (104 children; RR 0.33; 95% CI 0.13-0.83), but not at 1 or 2 years 44, 47 . The cumulative prednisolone dose after 2 years slightly but not significantly less in the cyclosporine treated group, and no significant elevations in blood pressure or falls in glomerular filtration rate (GFR) were documented. Eight weeks of add-on treatment with CsA at initial manifestation of SSNS seems to reduce the risk for younger children who experience relapses but does not abolish it.
Treatment of relapse:
Before starting steroid, infections should be ruled out and treated accordingly. Treatment should be started according to flow chart.
Fig.-3: Management of patients with Relapse nephrotic syndrome( IAP Guidelines)
Few data on steroid regimens for frequently relapsing and steroid-dependent NS: The ISKDC proposed that relapsing SSNS should be treated with daily prednisone (60mg/m 2 /day) till the child had been in remission for 3 consecutive days followed by 4 weeks of prednisone 40 .
Additional steroid therapy during inter-current infections: Children commonly relapse when they have infections. Children with steroid dependent NS had significantly fewer relapses during 2 years follow up if they received daily rather than alternate-day prednisolone during upper respiratory tract infections (36 children, mean difference -3.30; 95%CI -4.03 to -2.57) 44, 48 .
Steroid sparing agents:
The additional use of an alternative agent should be considered in patients with: (i) prednisolone threshold (for maintaining remission) higher than 0. d. Cyclosporine and Tacrolimus: both these agents have strong steroid sparing potential, with steroid discontinuation in patients following 6-9 months by tapering.
e. Rituximab:
When to refer to pediatric nephrologists 28 : Indication of referral of patients are:
• Onset below 1-year of age
• Family history of nephrotic syndrome
• Nephrotic syndrome with hypertension
• Gross/persistent microscopic hematuria, impaired renal function or external features (e.g. arthritis, serositis, rash)
• Complications: refractory edema, thrombosis, severe infections, steroids toxicity
• Resistance to steroid therapy Frequently relapsing or steroid dependent nephrotic syndrome KDIGO Guidelines: (Kidney Disease: Improving Global Outcomes) The daily dose of 60 mg/m 2 /day and the starting dose of 40mg/m 2 for alternate day therapy were used empirically by the ISKDC 49 and the APN 50 and have not been examined in RCTs. So, while these doses are recommended, the quality of evidence supporting these data is very low. Theoretical studies 51 have suggested that underdosage with prednisolone can occur if a perkilogram dose is used particularly in children weighing below 30 kg. Now KDIGO (Kidney Disease: Improving Global Outcomes) has published clinical practice guidelines on various glomerulo-nephritides including SSNS and SRNS in children using evidence-based principles 52 . Corticosteroid therapy (prednisone or prednisolone) for at least 12 weeks as a single daily dose starting at 60 mg/m 2 /day or 2 mg/kg/day to a maximum 60 mg/day for 4-6 weeks followed by alternate-day medication as a single daily dose starting at 40 mg/ m 2 or 1.5 mg/kg (maximum 40 mg on alternate days) and continued for 2-5 months with tapering of the dose. Comparison with previous guidelines for SSNS: 
Relapsing children:
For infrequently relapsing children, the US, Indian, and KDIGO guidelines use the same regimen originally used by the ISKDC and adapted by APN, while the French guidelines use a longer ones. For FR and SD SSNS, the US guidelines use a 3-month regimen of prednisone while the other guidelines suggest long courses of low-dose prednisone to maintain remission. The Indian and KDIGO guidelines suggest that second courses of alkylating agents not be used and the Indian guidelines recommend that chlorambucil not be used because of toxicity. Mizoribine is not considered in any guideline except KDIGO, which suggests that it should not be used 53 .
Steroid Resistant Nephrotic syndrome:
Children aged 1-18 years, are unable to achieve complete remission with corticosteroid therapy within 8weeks are termed as SRNS. Approximately 20% will be classified as steroid resistant 58, 59 .
Resistant nephrotic syndrome (SRNS) may have minimal change disease (MCD), mesangial proliferative glomerulonephritis (MesPGN) or focal segmental glomerulosclerosis (FSGS), although other histopathologic diagnoses also occur. If partial or complete remission is not achieved, 50 % risk of progression to end-stage kidney disease within 5 years of diagnosis 60, 61, 62 .
Evaluation
Children diagnosed with SRNS (initial or late) should undergo renal biopsy before starting specific treatment. About 10-20% patients with familial and sporadic SRNS and these patients are usually unresponsive to immunosuppressive medications, progresses rapidly to end stage renal disease. If facilities exist, mutational analysis should be offered to patients with: (i) congenital nephrotic syndrome (onset below 3 months of age) (ii) family history of SRNS, (iii) sporadic initial steroid resistance that does not respond to therapy with cyclophosphamide or calcineurin inhibitors, and (iv) pts with steroid resistant FSGS 53 . Baseline assessment of renal function, blood level of albumin and cholesterol, and quantification of starting urinary protein loss (spot urine protein to creatinine ratio in young children; 24-h protein excretion in older children) guides future evaluation of response to therapy. Patients should be evaluated for hepatitis B and C virus infection.
Management of SRNS:
The factor predicting renal outcome is the response of proteinuria to therapy rather than the renal histology. The aim of therapy in patients is thus to induce and maintain remission of proteinuria, while avoiding medication related adverse effects. Most regimen use a combination of immunosuppressive agents with prednisolone (given on alternate days) and an angiotensin converting enzyme inhibitor.
Drugs used in SRNS:
The benefits of immunosuppressive therapy must be assessed against the potential adverse effects at each relapse and remaining kidney function to determine whether it is in the child's interest to continue active therapy.
A. calcineurin inhibitor (CNI) as initial therapy for children with SRNS: CNI therapy be continued for a minimum of 6 months and then stopped if a partial or complete remission of proteinuria is not achieved. CNI is to be continued for a minimum of 12 months when at least a partial remission is achieved by 6 months. Low-dose corticosteroid therapy be combined with CNI therapy. Complete and partial remissions are less common in the presence of nephrotic syndrome associated with podocin mutations 63, 64, 65 . CNI therapy may induce at least a partial remission in these patients. Tacrolimus was compared with cyclosporine in one study 66 . and showed no significant difference in proteinuria control. The frequency of nephrotoxicity, hypertension, and diabetes mellitus were not different between cyclosporine and tacrolimus in this trial. Hypertrichosis and gingival hyperplasia were significantly more common with cyclosporine than with tacrolimus.
B. Mycophenolate mofetil: Observational studies involving 42 children with SRNS who were treated for a minimum of 6 months with MMF demonstrated a complete remission rate of 23-62%, a partial remission rate of 25-37%, and, no remission in 8-40% 67, 68, 69, 70 .
C. High-dose corticosteroids: Children with SRNS received either methylprednisolone or dexamethasone i.v. for six doses combined with prednisolone orally, and the short-term outcome was assessed at the end of a 2-week regimen. In the 138-patient with FSGS, RCT 68 , in the combination therapy MMF + dexamethasone, dexamethasone dose was high and had therapy duration of 6 months. In the MMF + dexamethasone arm, complete and partial remission rates were not greater than expected for MMF alone.
In a retrospective study of 52 children with SRNS and FSGS, the cumulative proportion of sustained remission was significantly higher in children treated with cyclosporine and methylprednisolone i.v. compared with cyclosporine with prednisone ora1ly 71 .
D. Alkylating agents: Children with SRNS demonstrated no significant differences in the number achieving remission with cyclophosphamide and prednisone compared with prednisone alone, with an increase in adverse effects in the cyclophosphamide groups. E. Rituximab: Observational studies 72, 73 suggest that it is not as effective in SRNS as in SSNS.
Monitoring response to therapy:
Patients should be monitored every month until response to therapy is demonstrated, and then every 2-3 month. The aim of treatment is the achievement of complete remission, but occurrence of partial remission is also satisfactory.
Drug monitoring: Most agents used in the therapy of SRNS require monitoring for adverse effects. Monitoring of drug levels is recommended when using either cyclosporine or tacrolimus. A 12-h trough level should be estimated about 2-week after introduction of therapy, after any dose change, and if suspecting drug toxicity or poor compliance. Trough levels in the range of 80-120 ng/ml for cyclosporine and 4-7 ng/ml for tacrolimus are acceptable. Renal biopsy is advised in patients receiving prolonged therapy (2-3 year) with calcineurin inhibitors. Histological features of nephrotoxicity include nodular hyalinosis or striped interstitial fibrosis and tubular atrophy.
KDIGO Glomerulonephritis Workgroup, 2012:
This guidelines has recommends 1. Minimum of 8 weeks treatment with corticosteroids to define steroid resistance.
2. The following are required to evaluate the child with SRNS
• a diagnostic kidney biopsy(FSGS lesions may be missed if the biopsy specimen has <20 glomeruli. The biopsy will also provide information on the degree of interstitial and glomerular fibrosis, which helps to assess prognosis.)
• evaluation of kidney function by glomerular filtration rate (GFR) or estimated GFR (eGFR) (Kidney function measured at the time of diagnosis is a predictor of the long-term risk for kidney failure)
• quantitation of urine protein excretion"( Proteinuria should be quantified at diagnosis and during treatment to allow treatment response to be defined as partial, complete, or no remission 61, 74, 75, 76, 77 . Urinary protein/creatinine ratio (uPCR) on the first morning specimen or measurements of 24-hurine protein may be used.) Two RCTs demonstrated a significant reduction in proteinuria with angiotens inconverting-enzyme inhibitors (ACEi) therapy using enalapril 78 and fosinopril 67 . Monitoring eGFR and serum potassium levels is recommended during RAS therapy.
b. Mycophenolate mofetil (MMF), high-dose corticosteroids, or a combination of these agents be considered in children who fail to achieve complete or partial remission with CNIs and corticosteroids. Cyclophosphamide not be given to children with SRNS. 85 12 MP (iv), CP (PO) and prednisolone vs CP 85.7% remission in MP (iv); (iv), MP (iv) and prednisolone 40% cent in CP (iv) 87 24 CP (iv), prednisolone for 6 months 29% remission CP, Cyclophosphamide; CsA, cyclosporin A; MP, methylprednisolone; PO, per oral; iv, intravenous;Ua/Uc, spot urine albumin to creatinine ratio. Remission refers to complete remission
Natural history and prognosis
Steroid responsiveness is the most important prognostic indicator of nephrotic syndrome. Approx. 60-80% of steroid-responsive nephrotic children will relapse and about 60% of those will have five or more relapses. Age older than 4 years at presentation and remission within 7-9 days of the start of steroid treatment in the absence of micro haematuria are predictive of fewer relapses 88, 89, 90 . In a natural-history study of 398 children, the proportion that became nonrelapsers rose from 44% at 1 year to 69% at 5 years, and 84% at l0 years. 91 For the steroid-resistant FSGS patients, the clinical course is typically very challenging. With current treatments, a few children will ultimately achieve a sustained remission with one of the second-line or third-line drugs. For patients with refractory nephrotic syndrome, progression to end-stage renal disease is inevitable. Some of these children have such a difficult clinical course because of refractory oedema, severe infections, thromboembolic complications, or a combination of these. For this subgroup, the ultimate treatment goal is renal transplantation, despite the haunting reality that FSGS will recur in about 25% of renal allografts 92 .
Immunosuppressive treatment is ineffective for patients with familial nephrotic syndrome; definitive treatment requires renal transplantation. Proper counseling is also vital. Parents are explained about the natural history of the disease and its outcome and adverse effect of repeated courses of high dose of medication. Parents' motivation and involvement is essential in the long term management of nephrotic patient. They should be advised for urine examination in every morning during a relapse, during inter-current infections and if there is mild peri-orbital puffiness. Parents should maintain a diary showing the results of urine protein examination, drugs received and infections. Parents are to ensure normal activity and school attendance. Patients with both sensitive and resistant patterns, require frequent monitoring of chemical course and biochemical response, timely management of the disease with complication, in order to enable satisfactory long term outcome.
